Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3077 Insights into the Practice Patterns, Challenges and the Role of a Shared Care Model in the Management of Neuroendocrine (NET) Patients in the Community

Introduction: Management of NET patients often involves a multidisciplinary approach,requiring collaboration between referring oncologists,surgeons,endocrinologists locally and NET specialty centers (NSC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Yelamanchili R

Authors: Radhika Y, Chan D, Thawer A, Lo D, Singh S,

Keywords: Shared care, NET, Local Medical Oncologists, NET specialty centers,

#1790 Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study

Introduction: Treatment options for advanced lung NETs are limited. The phase 3 CLARINET study demonstrated antitumour efficacy of somatostatin analogue (SSA) LAN 120mg vs PBO for metastatic gastroenteropancreatic grade 1/2 (Ki-67<10%) NETs, but prospective data on SSAs in advanced lung NETs are lacking.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Reidy-Lagunes D, Kulke M, Wolin E, Singh S, Ferone D,

Keywords: Lung NETs, lanreotide,

#1366 CommNETS: Formation of an International Commonwealth Countries NET Partnership

Introduction: Neuroendocrine tumours (NETs) care is challenging in Canada, Australia and New Zealand due to small populations in large geographical space, limited drug funding, and lack of NET awareness. There is a need for collaboration to focus research and improve care and outcomes for NET patients in these nations with similar health systems.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Singh S

Authors: Singh S, Lawrence B, Chan D, Pavlakis N, Segelov E,

Keywords: research, society,

#1240 Targeted Therapies as First Line Option in Very Advanced Unresectable Pancreatic Neuroendocrine Tumors

Introduction: Neuroendocrine tumors are an entity of rare, heterogeneous group of tumors that can arise from different sites within the body. Although number of different treatment types and modalities exist, chemotherapy remains as the first line option in the management of advance pancreatic NETS (pNETS); two targeted therapies, sunitinib and everolimus remains available only for second line and beyond in Canada.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Kavan P

Authors: Rho Y, Gilabert M, McLean J, Kavan P,

Keywords: targeted therapy, sunitinib, everolimus, PNET,

#1152 Appendiceal Neuroendocrine Tumor: Correlation Between Histopathological Factors

Introduction: Neuroendocrine tumours (NET) of the appendix are rare histopathological neoplasm’s detected following operation for appendicitis. Clinical decisions focuses on different pathological factors for further management. With the aim of defining contemporary patterns of care in surgical practice, a critical review of the records is carried to establish a correlation between different histopathological parameters

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Nada H

Authors: Nada H, Anania M, Luong T, Garcia-Hernandez J, Caplin M,

Keywords: Appendicectomy, Appendix, Carcinoid tumour(s), Neuroendocrine tumors,